Hari Anant Deshpande, MD

Associate Professor of Medicine (Medical Oncology)

Clinical Interests

  • Medical Oncology
  • Sarcoma

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Cancer Center, Yale: Endocrine Cancers Program | Head and Neck Cancers Program | Prostate and Urologic Cancers Program

General Urology

Medical Oncology

Yale Medical Group

Office of Cooperative Research

Board Certifications

  • Hematology (Internal Medicine) AB of Internal Medicine (1998)

  • Medical Oncology AB of Internal Medicine (1999)

Clinical Trials

Conditions Study Title
Prostate A Phase I/II Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in mCRPC
Prostate VT-464 in Patients W/Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Bladder WO29636: IMvigor 010 Study: Anti-(PD-L1) Antibody MPDL3280A Treatment vs. Versus Observation
Bladder S1314 (COXEN) with neoadjuvant therapy for localized, muscle invasive bladder cancer
Prostate, Phase I EC1169-01:Phase I study of PSA Targeting Tubulysin Conjugate EC1169 in Patients with recurrent mCRPC
Larynx, Lip, Oral Cavity and Pharynx, Thyroid Study of Pembrolizumab (MK-3475) for 1st Line Tx of Recurrent/Metastatic Squamous Cell Ca of H&N
Prostate ARMOR3-SV: Phase 3 trial of Galeterone Compared to Enzalutamide AR-V7 M1 CRPC
Bladder, Other Urinary JVDC 05 (RANGE): Ramucirumab Plus Docetaxel in Participants With Urothelial Cancer
Bladder, Other Urinary ML29725: Expanded access program for atezolizumab in metastatic urothelial cancer
Bladder, Lung, Other Digestive Organ, Other Urinary, Stomach, Phase I Ramucirumab + Pembro with Gastric or GEJ Adenocarcinoma, NSCLC or Tcell carcinoma of urothelium
Larynx, Lip, Oral Cavity and Pharynx, Phase I Ph I Study evaluating Safety, Tolerability, & Efficacy of MEDI4736 w/ Tremelimumab
Lip, Oral Cavity and Pharynx NRG-HN002: Testing less intensive treatment for selected low-risk patients with oropharyngeal cancer
Other Endocrine System A091202: Efatutazone vs. Placebo in Pts With Previously Treated, Unresectable Myxoid Liposarcoma
Lip, Oral Cavity and Pharynx Individualized treatment for nasopharyngeal cancer based on the patient's DNA
Bladder S1011: Standard or Extended Pelvic Lymphadenectomy in Pts to have Surgery for Invasive Bladder Canc
Brain and Nervous System, Pediatrics Germ Cell Tumor Pediatric CIRB study
Soft Tissue, Pediatrics ARST1321 Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Bones and Joints, Pediatrics AEWS1221 Newly Diagnosed Metastatic Ewing Sarcoma
Bladder, Phase I Novartis BGJ398: A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Kidney S0931: Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

Edit this profile

Contact Info

Hari Anant Deshpande, MD
Patient Care Locations
Yale Cancer CenterSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste 4th Floor

New Haven, CT 06511
View on map...
Smilow Cancer CareYale-New Haven Hospital Saint Raphael Campus
1450 Chapel Street, Ste Suite A

New Haven, CT 06511
View on map...
Mailing Address
PO Box 208028
333 Cedar Street,

New Haven, CT 06520-8028